Skip to content

Search

New patient folder

Our new and improved patient folder is a comprehensive resource to help families navigate a new type 1 diabetes diagnosis, now and into the future.

Food and nutrition

Discover essential insights on food and nutrition for Type 1 Diabetes, from carb counting to meal planning.

Pump Comparison tool

Pump Comparison tool . This easy-to-use updated comparison tool is designed to help you pick the right device for your family.

Be involved

Find out how to participate in our research and community groups.

Clinical Trials

We are in a new era of T1D care. We can now identify and provide care for people across a spectrum of T1D, from early-stage T1D to symptomatic insulin requiring T1D (Stage 3 and Stage 4). And for the first time since the discovery of insulin over 100 years ago, Australia has approved a new therapy, Teplizumab.

A community-led, trauma-informed psychosocial intervention to improve health outcomes of children and young people with Type-1 diabetes

T1D can be a traumatic diagnosis for children and young people, and often involves strict adherence to painful treatments, comorbid mental health conditions, and shortened life expectancy.

DiabHQ

The DiabHQ Patient Portal app is now available to WA children and families living with Type 1 diabetes.

Early Dysglycemia Is Detectable Using Continuous Glucose Monitoring in Very Young Children at Risk of Type 1 Diabetes

Continuous glucose monitoring (CGM) can detect early dysglycemia in older children and adults with presymptomatic type 1 diabetes and predict risk of progression to clinical onset. However, CGM data for very young children at greatest risk of disease progression are lacking. 

Environmental Determinants of Islet Autoimmunity (ENDIA) longitudinal prospective pregnancy to childhood cohort study of Australian children at risk of type 1 diabetes: parental demographics and birth information

The Environmental Determinants of Islet Autoimmunity Study is an ongoing Australian prospective cohort study investigating how modifiable prenatal and early-life exposures drive the development of islet autoimmunity and type 1 diabetes in children. In this profile, we describe the cohort's parental demographics, maternal and neonatal outcomes and human leukocyte antigen genotypes.